Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

BioRestorative Therapies gains media attention for key regenerative medicine programs

Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and...

June 20, 2024

Developments

Former Hepion CEO sues over departure; cites bad faith dealings with investor

Former Hepion Pharmaceuticals (NASDAQ:HEPA) CEO, Robert Foster, PharmD, PhD, is suing the company and its Board members for illegal termination of his employment, breach of contract, and breach of the covenant of good...

June 13, 2024

Developments

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

BioRestorative Therapies (NASDAQ:BRTX) reports that it is engaged in substantive discussions with an undisclosed commercial stage regenerative medicine company concerning the licensing of its proprietary off-the-shelf...

June 13, 2024

Developments

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage Therapeutics (NASDAQ:SAGE) announced its Phase 2 SURVEYOR study has met its primary endpoint showing a significant difference in HD-Cognitive Assessment Battery composite scores at baseline between healthy...

June 11, 2024

Developments

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Viridian Therapeutics (NASDAQ:VRDN) announced details of its plans to initiate two Phase 3 clinical trials of its subcutaneous VRDN-003 product candidate for patients with active and chronic moderate-to-severe thyroid...

June 11, 2024

Developments

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost...

June 5, 2024

Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that...

June 5, 2024

Developments

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Trinity Biotech (NASDAQ: TRIB) has announced the launch of its continuous glucose monitoring (CGM) microsite to provide insights into the development of its next-generation CGM biosensor technology and AI-driven health...

June 3, 2024

Developments

Verve Therapeutics appoints Troy Lister as CSO

Verve Therapeutics (NASDAQ:VERVE) has appointed Troy Lister, Ph.D., as CSO, effective June 21, 2024, succeeding Andrew Bellinger, M.D., Ph.D., who will serve in an advisory capacity. Currently, Dr. Lister serves as...

June 3, 2024

Developments

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

Closely-held Lucy Therapeutics (LucyTX) raised $12.5 million in additional funding to further the company’s research programs for Alzheimer’s and Parkinson’s diseases and continue its development of a novel drug target...

May 29, 2024

Developments

BerGenBio announces NCI clinical collaboration with UT Health San Antonio and Swedish Orphan Biovitrum AV

BerGenBio ASA (OSE: BGBIO) has announced that it has entered into a clinical trial agreement with the Mays Cancer Center at UT Health San Antonio and Swedish Orphan Biovitrum AV to study BerGenBio’s selective AXL...

May 29, 2024

Developments

Elixir Medical reports positive data from stress system to treat calcified lesions trial

Closely-held Elixir Medical has announced positive results from its PINNACLE I clinical trial evaluating the safety and effectiveness of its novel LithiX Hertz Contact Lithotripsy (IVL) System that uses stress to treat...

May 17, 2024

Developments

Takeda’s dengue vaccine receives WHO prequalification

Takeda (TSE: 4502/NYSE: TAK) TAK-003, a new dengue vaccine, has obtained WHO prequalification. WHO has also recommended TAK-003 for children aged six to 16 in regions that are at risk of the mosquito-borne viral disease...

May 16, 2024

Developments

Profound Medical receives FDA 510(k) clearance for ‘Contouring Assistant’ AI module enabling creation of automated TULSA treatment plan

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it has received FDA 510(k) clearance for its second TULSA-AI module, Contouring Assistant, a machine learning-based prostate segmentation tool, for use in...

May 14, 2024

Developments

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that a total of 25 clinical presentations highlighting TULSA procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer...

May 6, 2024

Developments

BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform

BioRestorative Therapies (NASDAQ:BRTX) announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics. The goal of this transformative agreement is to combine BioRestorative’s deep...

April 30, 2024

Developments

PharmaJet creates two SABs

Closely-held PharmaJet created two scientific advisory boards (SABs) – infectious diseases and oncology – comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping...

April 1, 2024

Developments

LENZ Therapeutics completes merger with Graphite Bio

LENZ Therapeutics (NASDAQ:LENZ) has completed its merger with Graphite Bio in an all-stock transaction. LENZ is advancing its lead assets, LNZ100 and LNZ101, which are both preservative-free, single-use, once-daily eye...

March 22, 2024

Developments

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a non-exclusive collaboration with Siemens Healthineers (XETRA:SHL) aimed at laying the groundwork for Profound to begin marketing a complete therapeutics solution...

February 28, 2024

Developments

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform

IntelGenx (TSX:IGX; OTCQB:IGXT) announced positive results from a proof-of-concept study, conducted through a research collaboration with the University Prince Edward Island (UPEI), to assess the palatability, owner...

February 5, 2024

Developments

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

BioRestorative Therapies (NASDAQ:BRTX) announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society’s 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded...

February 5, 2024

Developments

Japan Patent Office issues decision to grant patent for Anixa’s ovarian cancer vaccine

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application covering the company’s ovarian cancer...

January 23, 2024

Subscribe